Chemotherapy-induced pulmonary toxicity isn't well understood. It's believed that the reason is direct harm to the lung parenchyma and also the altered proliferation and migration of pneumocytes. The harm caused by the cytotoxic agents causes destruction of the alveolar and interstitial epithelium, making capillary exchange of oxygen and co2 difficult.
Alveolitis, interstitial pneumonitis, and fibrosis can happen, which lessen the functional residual capacity and elasticity of the lungs. These effects are significant since they're the precursors to life-threatening respiratory failure.
Awareness of the risk factors related to pulmonary toxicity is essential in identifying patients predisposed to pulmonary damage. These risk factors range from the utilization of pulmonary-toxic drugs, pre-existing lung disease, age over the age of Six decades, renal dysfunction, high-dose oxygen therapy, good reputation for smoking, and concomitant radiotherapy towards the chest. Pulmonary toxicity may develop within times of therapy or could have a chronic onset after entire time of therapy.
Both cytotoxic agents that commonly cause pulmonary damage are bleomycin and busulfan. The pulmonary damage brought on by bleomycin is dose-related; patients who get a cumulative dose in excess of 450 units show a greater incidence of toxicity compared to those who get a lower cumulative dose. In busulfan therapy, the busulfan lung syndrome can happen and it has an undesirable prognosis.
Dyspnea may be the cardinal characteristic of chemotherapy-induced pulmonary toxicity. Other signs or symptoms are fever, fatigue, dry cough, tachypnea, and rales. Heart problems is unusual but may occur with paclitaxel and docetaxel administration. The very best intervention for pulmonary alterations is prevention.
Get yourself a baseline assessment of pulmonary function, including a chest x-ray, pulmonary function tests, and arterial blood gas analysis. Take notice of the patient's respiratory rate and breathing patterns, and note any changes with position and exertion.
Ask the individual whether she or he has problems performing activities of everyday living. Review using the patient the twelve signs and the signs of pulmonary toxicity and measures to help with these complaints. Instruct the individual to prevent smoking and contact with irritants for example noxious gases and aerosol sprays.
Teach the individual to breathe properly and also to alternate periods of activity and rest. When the patient is undergoing therapy and develops severe pulmonary complications, consider discontinuing the drug. Monitor the dose given for bleomycin therapy; the recommended maximum is 400 to 500 units. Think about the utilization of steroid prophylaxis for patients who develop capillary leak syndrome.
Stay away from high fractions of inspired oxygen to avoid further lung damage. Provide supportive therapy, for example loop diuretics to lower pulmonary congestion or vasodilators or bronchodilators when needed. Restrict fluid intake. Position patient for comfort.
Our website is not responsible for the information contained by this article. Webworldarticles.com is a free articles resource thus practically any visitor can submit an article. However if you notice any copyrighted material, please contact us and we will remove the article(s) in discussion right away.
This article was sent to us by:
Duane Owens at
07262011
1. Alkylating agents used in chemotherapy to fight cancer cells
All articles in this directory are property of their respective authors. Additionally, read our Privacy Policy
© 2010 WebWorldarticles.com - All Rights Reserved. Partners: Gunblade Saga